Related Experiment Video
Updated: Nov 19, 2025
09:39
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
7.1K
DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously
Roland Beckmann1, Kristian Jensen2,3, Sebastian Fenn2
1Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany. pred.dutafabs@roche.com.
Nature Communications
|January 30, 2021
Summary
Researchers developed dual targeting Fab (DutaFab) molecules, a novel bispecific antibody platform. These DutaFabs effectively target VEGFA and PDGF-BB, showing enhanced efficacy in vivo.
Area of Science:
- Biotechnology and Pharmaceutical Sciences
- Immunology and Cancer Therapeutics
Background:
- Antibody engineering seeks novel formats for enhanced therapeutic capabilities.
- Bispecific antibodies offer potential for simultaneous targeting of multiple disease-related molecules.
Purpose of the Study:
- To develop and characterize a novel modular bispecific antibody platform, termed dual targeting Fab (DutaFab).
- To generate and evaluate DutaFabs targeting Vascular Endothelial Growth Factor A (VEGFA) and Platelet-Derived Growth Factor BB (PDGF-BB) for therapeutic applications.
Main Methods:
- Design and construction of DutaFab molecules with independent H-side and L-side paratopes.
- Characterization of DutaFab binding affinities, stability, and solubility.
- In vivo efficacy studies comparing DutaFab therapy with anti-VEGF monotherapy.
Main Results:
- DutaFabs demonstrated high affinity binding to VEGFA and PDGF-BB.
- The developed DutaFabs exhibited favorable physico-chemical stability and solubility.
- In vivo studies showed superior efficacy of DutaFabs compared to anti-VEGF monotherapy.
Conclusions:
- The DutaFab platform enables modular generation of bispecific antibodies with simultaneous dual-targeting capabilities.
- DutaFabs targeting VEGFA and PDGF-BB represent a promising new class of antibody therapeutics with enhanced in vivo efficacy.
- This novel antibody format is currently under evaluation in clinical trials.
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Related Concept Videos
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.5K
01:24Tagging and Fusion Proteins
7.8K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
7.8K
01:26Targets for Drug Action: Overview
9.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.0K
01:57Protein Complexes with Interchangeable Parts
2.7K
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
2.7K